What clinical trials have been conducted on tirzepatide (Mounjaro)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clinical Trials on Tirzepatide

Yes, extensive clinical trial programs have evaluated tirzepatide across multiple populations, with the SURMOUNT trials demonstrating exceptional efficacy for obesity and the SURPASS trials establishing its role in type 2 diabetes management.

Major Trial Programs

SURMOUNT Trials (Obesity)

The SURMOUNT program represents the primary evidence base for tirzepatide in obesity management 1:

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications, excluding diabetes. At 72 weeks, tirzepatide 15 mg achieved 22.5% mean weight reduction, with nearly 40% of participants losing ≥25% body weight 2. This trial established tirzepatide as producing the largest weight loss of any approved obesity medication.

SURMOUNT-2 specifically studied 938 adults with both obesity and type 2 diabetes. Despite the known dampening effect of diabetes on weight loss efficacy, tirzepatide 10 mg and 15 mg still achieved 12.8% and 14.7% weight reduction respectively at 72 weeks, alongside 2.2% A1C reduction 3. Notably, nearly half of participants achieved normal A1C values (<5.7%) with minimal hypoglycemia.

SURMOUNT-3 and SURMOUNT-4 examined weight maintenance strategies. SURMOUNT-3 demonstrated that combining tirzepatide with intensive lifestyle intervention produced up to 26.6% weight reduction. SURMOUNT-4 used a withdrawal design: participants who achieved 20.9% weight loss during a 36-week open-label period were randomized to continue tirzepatide or switch to placebo. Those continuing tirzepatide maintained and augmented their weight loss (total 25.3% reduction at 88 weeks), while those switched to placebo regained substantial weight 4.

SURMOUNT-CN validated efficacy in Chinese adults with obesity, showing 13.6% and 17.5% weight reduction with 10 mg and 15 mg doses respectively 5.

SURMOUNT-MAINTAIN (most recent, 2026) demonstrated that continuing tirzepatide at maximum tolerated dose (MTD) maintained 21.9% weight reduction at 112 weeks, while dose reduction to 5 mg maintained 16.6% reduction—both superior to placebo at 9.9% 6. This trial provides critical evidence that long-term treatment is necessary for sustained weight management.

SURPASS Trials (Type 2 Diabetes)

The SURPASS program established tirzepatide's glycemic efficacy in type 2 diabetes 1:

Across the SURPASS trials, tirzepatide demonstrated A1C reductions of 1.9-2.0%, with >87% of participants reaching A1C target <7%. The trials included monotherapy (SURPASS-1), combination with metformin/sulfonylureas/SGLT2 inhibitors (SURPASS-2, -3, -4), and combination with basal insulin (SURPASS-5).

Critical cardiovascular data: A prespecified post hoc analysis showed tirzepatide did not increase MACE risk in participants with type 2 diabetes. The ongoing SURPASS CVOT (NCT04255433) is specifically evaluating cardiovascular outcomes in type 2 diabetes patients 1.

Cardiovascular Outcomes Trials

SURMOUNT-MMO is an ongoing cardiovascular outcomes trial investigating both primary and secondary CV risk prevention in individuals with obesity without diabetes (NCT05556512) 1. This represents a critical knowledge gap, as tirzepatide currently lacks the high-certainty cardiovascular benefit data that semaglutide has established.

SUMMIT trial enrolled 731 participants with heart failure with preserved ejection fraction (HFpEF) and obesity. Over 104 weeks, tirzepatide significantly reduced the composite endpoint of first HF event or cardiovascular death (HR 0.62,95% CI 0.41-0.95), alongside improvements in quality of life, functional capacity, and reductions in NT-proBNP 7.

Specialized Population Trials

SURPASS-PEDS (2025) evaluated tirzepatide in 99 children and adolescents (ages 10-<18 years) with type 2 diabetes. At 30 weeks, pooled tirzepatide reduced HbA1c by 2.23% versus placebo increase of 0.05%, with sustained effects to 52 weeks. BMI reductions were 7.4% and 11.2% for 5 mg and 10 mg doses respectively 8.

Type 1 diabetes trial (2026): A phase 2 study in 24 adults with type 1 diabetes and BMI >30 showed 8.8% weight loss at 12 weeks with tirzepatide 5 mg, alongside 0.4% HbA1c improvement and 35% reduction in total daily insulin dose, without significant adverse events 9.

Key Efficacy Findings Across Trials

Weight reduction hierarchy: Tirzepatide 15 mg > 10 mg > 5 mg, with all doses superior to GLP-1 receptor agonists. Network meta-analysis confirmed tirzepatide 10 and 15 mg produced 4.85% and 6.26% greater weight loss than semaglutide 2.4 mg respectively 10.

Cardiometabolic benefits: Beyond weight and glycemic control, trials demonstrated improvements in triglycerides, blood pressure, and prevention of prediabetes progression to type 2 diabetes 1.

FDA approvals based on trials: Obesity (2023), type 2 diabetes (2022), and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024) 1.

Safety Profile Across Trials

Gastrointestinal adverse events (nausea, diarrhea, vomiting) were most common, predominantly mild-to-moderate, occurring during dose escalation and decreasing over time 11. Treatment discontinuation rates due to adverse events ranged from 4.3-7.1% across tirzepatide doses versus 2.6% for placebo 11.

Nutritional status analysis: Post hoc analysis of SURMOUNT-1-4 (N=4,726) found macronutrient malnutrition TEAEs were uncommon (0.03-0.06% vs 0% placebo), and only 0.38% reached BMI <18.5 kg/m² 12. However, systematic vitamin and mineral assessment was not performed, representing a limitation.

Clinical Decision-Making Context

When choosing between GLP-1 receptor agonists and tirzepatide, the 2025 BMJ guideline emphasizes weighing the higher certainty of cardiovascular and kidney benefits offered by GLP-1 receptor agonists against the larger weight loss benefits offered by tirzepatide 13. For patients at higher cardiovascular risk, tirzepatide should generally not replace medications with proven cardiovascular benefit unless combined with SGLT2 inhibitors.

References

Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Research

Tirzepatide Once Weekly for the Treatment of Obesity.

The New England journal of medicine, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.